Please login to the form below

Not currently logged in
Email:
Password:

US pharma to woo back trust

Pharmaceutical companies in the US are developing voluntary guidelines to improve advertising on television and through other media in an attempt to win back public trust, according to an industry association.

Pharmaceutical companies in the US are developing voluntary guidelines to improve advertising on television and through other media in an attempt to win back public trust, according to an industry association.

Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America (PhRMA), said that there is “obviously room for improvement” in the way the industry operates and announced that the organisation will produce a set of advertising principles for pharma companies to follow.

Risks and benefits associated with treatments must be seriously addressed in an ad, he added. While Tauzin hopes that the principles will help to settle a number of complaints about product advertising, Consumer Union, the publisher of Consumer Reports said that voluntary promises were not enough and cast doubt over whether patients would be adequately informed as a result.

Rob Schneider, manager of the Consumer Union project to improve drug safety and prices, asked: “Can we really expect drug makers to voluntarily tell us about possible problems in these ads when they know it will hurt their sales?”

Tauzin who left Congress last year and took the helm at the PhRMA in January wants to restore the pharma industry's reputation. His appointment came under fire because he was instrumental in pushing a Medicare bill through Congress that included provisions favouring the industry.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics